Net Cash Provided by (Used in) Financing Activities of ANAPTYSBIO, INC from 31 Dec 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
ANAPTYSBIO, INC annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2015 to 31 Dec 2025.
  • ANAPTYSBIO, INC Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $28,590,000, a 110% decline year-over-year.
  • ANAPTYSBIO, INC annual Net Cash Provided by (Used in) Financing Activities for 2025 was $132,613,000, a 204% decline from 2024.
  • ANAPTYSBIO, INC annual Net Cash Provided by (Used in) Financing Activities for 2024 was $127,054,000.
  • ANAPTYSBIO, INC annual Net Cash Provided by (Used in) Financing Activities for 2023 was $59,297,000, a 235% decline from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

ANAPTYSBIO, INC Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $132,613,000 -$259,667,000 -204% 01 Jan 2025 31 Dec 2025 10-K 03 Mar 2026 2025 FY
2024 $127,054,000 +$186,351,000 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2026 2025 FY
2023 $59,297,000 -$103,314,000 -235% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2026 2025 FY
2022 $44,017,000 -$208,281,000 -83% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $252,298,000 +$253,177,000 01 Jan 2021 31 Dec 2021 10-K 11 Mar 2024 2023 FY
2020 $879,000 +$3,614,000 +80% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 $4,493,000 -$227,857,000 -102% 01 Jan 2019 31 Dec 2019 10-K 07 Mar 2022 2021 FY
2018 $223,364,000 -$69,089,000 -24% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $292,453,000 +$283,825,000 +3290% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
2016 $8,628,000 -$30,775,000 -78% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $39,403,000 01 Jan 2015 31 Dec 2015 10-K 05 Mar 2018 2017 FY

ANAPTYSBIO, INC Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $28,590,000 -$14,957,000 -110% 01 Jan 2025 31 Mar 2025 10-Q 05 May 2025 2025 Q1
Q1 2024 $13,633,000 +$23,941,000 +64% 01 Jan 2024 31 Mar 2024 10-Q 05 May 2025 2025 Q1
Q1 2023 $37,574,000 -$42,183,000 -915% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q1 2022 $4,609,000 +$4,442,000 +2660% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q1 2021 $167,000 +$1,506,000 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q1 2020 $1,339,000 -$38,000 -2.9% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q1 2019 $1,301,000 +$82,000 +5.9% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q1 2018 $1,383,000 -$82,087,000 -102% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q1 2017 $80,704,000 +$80,979,000 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q1 2016 $275,000 01 Jan 2016 31 Mar 2016 10-Q 12 May 2017 2017 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.